Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.
Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T, Okita H, Koshinaga T, Oue T, Hinotsu S, Nakadate H, Horie H, Fukuzawa M, Kaneko Y.
Ohshima J, et al. Among authors: watanabe n.
Pediatr Blood Cancer. 2012 Sep;59(3):499-505. doi: 10.1002/pbc.24093. Epub 2012 Mar 27.
Pediatr Blood Cancer. 2012.
PMID: 22457227